Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

1.9K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.9K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Direct-Acting Cholinergic Agonists: Pharmacological Actions00:59

Direct-Acting Cholinergic Agonists: Pharmacological Actions

2.5K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
2.5K
Direct-Acting Cholinergic Agonists: Pharmacokinetics01:31

Direct-Acting Cholinergic Agonists: Pharmacokinetics

2.0K
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
2.0K
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:22

Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

2.4K
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
2.4K
Drugs Acting on Autonomic Ganglia: Blockers01:28

Drugs Acting on Autonomic Ganglia: Blockers

1.8K
Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups:
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ACTH-dependent Cushing's syndrome in MEN1: When multiple tumors complicate the diagnosis.

Annales d'endocrinologie·2026
Same author

Overcoming barriers to the prescription/dispensation of take-home naloxone among French primary care professionals: a regional training initiative.

European journal of public health·2026
Same author

Acromegaly diagnosis.

The Journal of clinical endocrinology and metabolism·2026
Same author

Consensus on acromegaly complications: an update.

Pituitary·2026
Same author

EEG-based brain-computer interface with immersive virtual reality for phantom limb pain: a single-center pilot neurofeedback trial.

Frontiers in human neuroscience·2026
Same author

Normative data for insulin-like growth factor-1 and insulin-like growth factor binding protein-3 and their determinants in healthy adult males from india: the INDIIGo study.

Scientific reports·2025
Same journal

Gauze swabbing technique for safe dissection of pituitary tumors.

Pituitary·2026
Same journal

Postoperative changes in circulating brain injury biomarkers in relation to long-term fatigue and cognitive outcomes after surgery for nonfunctioning pituitary adenomas.

Pituitary·2026
Same journal

Pituitary metastasis as an endocrine-neuro-ophthalmologic emergency: clinical red flags and outcomes from a contemporary tertiary-center series.

Pituitary·2026
Same journal

GH responsiveness to corticotropin-releasing hormone identifies corticotroph-like somatotroph adenomas in acromegaly.

Pituitary·2026
Same journal

Etomidate in severe hypercortisolism: early cortisol kinetics and clinical outcomes in a real-world cohort.

Pituitary·2026
Same journal

The effect of hypoprolactinemia on cardiometabolic effects of rosuvastatin in men: A matched Cohort Pilot Study.

Pituitary·2026
See all related articles

Related Experiment Video

Updated: Mar 9, 2026

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
07:43

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

20.0K

Cabergoline in acromegaly.

Emmanuelle Kuhn1,2,3,4, Philippe Chanson5,6,7,8

  • 1Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre Service d'Endocrinologie et des Maladies de la Reproduction, 78 rue du Général Leclerc, 94275, Le Kremlin-Bicêtre, France.

Pituitary
|December 28, 2016
PubMed
Summary
This summary is machine-generated.

Cabergoline effectively treats acromegaly, a rare growth hormone disorder. This well-tolerated drug normalizes IGF-I levels in many patients, alone or with other therapies, offering a safe and affordable treatment option.

Keywords:
AcromegalyCabergolinePegvisomantPituitary adenomaSomatostatin analogues

More Related Videos

Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications
09:39

Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications

Published on: January 27, 2014

13.1K
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

3.6K

Related Experiment Videos

Last Updated: Mar 9, 2026

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
07:43

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

20.0K
Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications
09:39

Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications

Published on: January 27, 2014

13.1K
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

3.6K

Area of Science:

  • Endocrinology
  • Pharmacology

Background:

  • Acromegaly results from pituitary adenoma-induced growth hormone (GH) hypersecretion.
  • Untreated acromegaly leads to severe comorbidity and premature mortality.
  • Standard treatment involves surgery, with medical options for persistent GH/IGF-I hypersecretion.

Purpose of the Study:

  • To evaluate the efficacy and safety of cabergoline in managing acromegaly.
  • To assess cabergoline's role as monotherapy and in combination with other treatments.

Main Methods:

  • Review of existing literature on cabergoline use in acromegaly.
  • Analysis of studies reporting IGF-I normalization rates with cabergoline monotherapy and combination therapy.
  • Assessment of cabergoline's safety profile, particularly regarding cardiac valvulopathy.

Main Results:

  • Cabergoline monotherapy normalizes IGF-I in over 33% of acromegaly patients.
  • Add-on cabergoline therapy achieves normal IGF-I in 40-50% of patients unresponsive to somatostatin receptor ligands.
  • Combination therapy with pegvisomant and cabergoline aids IGF-I normalization while minimizing pegvisomant dosage.
  • Cabergoline is well-tolerated and does not appear to induce heart valve disease.

Conclusions:

  • Cabergoline is an effective and safe therapeutic option for acromegaly.
  • Its utility spans monotherapy, add-on treatment, and combination strategies.
  • Cabergoline offers an inexpensive, well-tolerated alternative for managing growth hormone hypersecretion.